Our additional preliminary studies demonstrate that dual targeting of multiple myeloma cells and BM-CAFs by CAR-T cells is ...

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...

Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sanofi’s Sarclisa combined with Velcade ...

newly-diagnosed multiple myeloma (NDMM), there was no significant difference identified in the level of minimal residual disease (MRD) negativity with the use of single vs tandem autologous stem cell ...

Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...

The week after the race, I learned I had multiple myeloma ... low-dose radiation of the tumor designed to reduce the myeloma in my body and prepare me for a stem-cell transplant. I tolerated these ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma ...

scientists have tracked the journey of stem cells years after a transplant, uncovering details about a medical process that has puzzled doctors for over 50 years. This groundbreaking study offers ...

Multiple myeloma is a type of cancer where plasma ... induction therapy with the above or similar drugs. At times, a stem cell transplant may be recommended. A long term, follow-up study from ...

By analyzing the mutations that occur throughout life in the donor and recipient's stem cells, they could track how many stem cells had survived the transplant process and continued to produce new ...